Nuveen
ANIP icon

Nuveen’s ANI Pharmaceuticals ANIP Stock Holding History

Nuveen’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4M Buy
415,024
+12,667
+3% +$1.02M 0.01% 925
2026
Q1 		$30.9M Buy
402,357
+15,255
+4% +$1.19M 0.01% 891
2025
Q4 		$30.6M Sell
387,102
-7,973
-2% -$690K 0.01% 899
2025
Q3 		$36.2M Buy
395,075
+24,099
+6% +$1.97M 0.01% 788
2025
Q2 		$24.2M Buy
370,976
+322,375
+663% +$21M 0.01% 975
2025
Q1 		$3.25M Sell
48,601
-1,042
-2% -$62.2K ﹤0.01% 2135
2024
Q4 		$2.74M Sell
49,643
-132,385
-73% -$7.6M ﹤0.01% 2251
2024
Q3 		$10.9M Sell
182,028
-137,114
-43% -$8.36M ﹤0.01% 1551
2024
Q2 		$20.3M Buy
319,142
+72,986
+30% +$4.74M 0.01% 1122
2024
Q1 		$17M Buy
246,156
+86,862
+55% +$5.24M 0.01% 1274
2023
Q4 		$8.78M Sell
159,294
-62,137
-28% -$3.42M ﹤0.01% 1672
2023
Q3 		$12.9M Buy
221,431
+180,491
+441% +$10.4M ﹤0.01% 1325
2023
Q2 		$2.2M Hold
40,940
– – ﹤0.01% 2301
2023
Q1 		$1.63M Sell
40,940
-3,977
-9% -$168K ﹤0.01% 2423
2022
Q4 		$1.81M Sell
44,917
-6,115
-12% -$230K ﹤0.01% 2433
2022
Q3 		$1.64M Sell
51,032
-602
-1% -$20.6K ﹤0.01% 2501
2022
Q2 		$1.53M Buy
51,634
+12,560
+32% +$362K ﹤0.01% 2578
2022
Q1 		$1.05M Buy
39,074
+3,427
+10% +$128K ﹤0.01% 2803
2021
Q4 		$1.6M Sell
35,647
-3,167
-8% -$136K ﹤0.01% 2675
2021
Q3 		$1.12M Sell
38,814
-2,200
-5% -$68.4K ﹤0.01% 2955
2021
Q2 		$1.44M Sell
41,014
-5,176
-11% -$176K ﹤0.01% 2859
2021
Q1 		$1.67M Buy
46,190
+3,922
+9% +$123K ﹤0.01% 2698
2020
Q4 		$1.23M Buy
42,268
+3,841
+10% +$110K ﹤0.01% 2732
2020
Q3 		$1.08M Buy
38,427
+137
+0.4% +$4.08K ﹤0.01% 2650
2020
Q2 		$1.24M Sell
38,290
-20,556
-35% -$737K ﹤0.01% 2527
2020
Q1 		$2.4M Sell
58,846
-3,017
-5% -$160K ﹤0.01% 2102
2019
Q4 		$3.81M Sell
61,863
-5,056
-8% -$335K ﹤0.01% 2128
2019
Q3 		$4.88M Sell
66,919
-19,100
-22% -$1.43M ﹤0.01% 1967
2019
Q2 		$7.07M Buy
+86,019
New +$6.12M ﹤0.01% 1802

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's ANIP Position: Q2 2026 in Review

Nuveen increased its ANI Pharmaceuticals (ANIP) stake by 3.1% in Q2 2026, buying an estimated $1.02M and bringing the position to 415,024 shares worth $34.4M. The position accounts for 0.01% of the portfolio, ranked #925.

Nuveen first reported a position in ANIP in Q2 2019 and has held it in 29 quarters since. The position peaked at $36.2M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Nuveen held 415,024 shares of ANI Pharmaceuticals worth $34.4M as of Q2 2026.
  • Nuveen bought 12,667 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.02M.
  • ANI Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #925 holding.
  • Nuveen first reported a position in ANI Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's ANI Pharmaceuticals position peaked at $36.2M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.